A concise review of non-alcoholic fatty liver disease

Atherosclerosis. 2015 Mar;239(1):192-202. doi: 10.1016/j.atherosclerosis.2015.01.001. Epub 2015 Jan 13.


Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and the incidence of which is rising rapidly due to the increasing epidemic of obesity in both adults and children. The initial accumulation of fat followed by subsequent inflammation is central to the development of liver damage, and is critically influenced by host factors including age, gender, presence of diabetes, genetic polymorphisms and more recently by the gut microbiome. An increasing body of data suggest that NAFLD is also an independent risk factor of cardiovascular disease, which remains the commonest cause of mortality in such patients. This review focusses on the pathogenesis of NAFLD, and the evolution of new approaches to the management and treatment of NAFLD.

Keywords: Cardiovascular disease; Dyslipidaemia; Insulin resistance; Non-alcoholic fatty liver disease; Pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipose Tissue / pathology
  • Adult
  • Apoptosis
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / complications*
  • Child
  • Dyslipidemias / blood
  • Fatty Acids, Nonesterified / blood
  • Fatty Liver / physiopathology
  • Female
  • Fibrosis / physiopathology
  • Hepatocytes / cytology
  • Humans
  • Insulin Resistance
  • Male
  • Non-alcoholic Fatty Liver Disease / complications*
  • Non-alcoholic Fatty Liver Disease / diagnosis*
  • Non-alcoholic Fatty Liver Disease / therapy
  • Obesity / complications
  • Polymorphism, Genetic
  • Risk Factors
  • Triglycerides / blood


  • Fatty Acids, Nonesterified
  • Triglycerides